ATS 2020
COPD Maintenance Therapy: Adverse Outcomes With Tiotropium/Olodaterol vs LABA/ICS
In patients with COPD, tiotropium/olodaterol was associated with a lower risk for escalation to triple therapy or the development of adverse outcomes compared with LABA/ICS.
